Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).

Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group.

Br J Haematol. 2010 Oct;151(2):143-51. doi: 10.1111/j.1365-2141.2010.08331.x.

2.

Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.

Yoo C, Kim S, Sohn BS, Kim JE, Yoon DH, Huh J, Lee DH, Kim SW, Lee JS, Suh C.

Korean J Intern Med. 2010 Sep;25(3):301-8. doi: 10.3904/kjim.2010.25.3.301. Epub 2010 Aug 31.

3.

A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.

Procházka V, Pytlík R, Janíková A, Belada D, Sálek D, Papajík T, Campr V, Fürst T, Furstova J, Trněný M.

PLoS One. 2014 Jul 24;9(7):e102594. doi: 10.1371/journal.pone.0102594. eCollection 2014.

4.

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.

J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.

5.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM.

Blood. 2007 Mar 1;109(5):1857-61. Epub 2006 Nov 14.

6.

Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.

Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH, Yu YB.

Ann Hematol. 2013 Nov;92(11):1513-20. doi: 10.1007/s00277-013-1807-0. Epub 2013 Jun 18.

PMID:
23775580
7.

Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.

Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, Takahashi S, Komatsu H, Ikeda K, Takeuchi K, Tanimoto M, Hatake K.

Ann Oncol. 2009 Mar;20(3):526-33. doi: 10.1093/annonc/mdn677. Epub 2008 Dec 12.

PMID:
19074749
8.

[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].

Liu W, Wang X, Zhang C, Xie Y, Lin N, Tu M, Ping L, Ying Z, Deng L, Huang H, Wu M, Sun Y, Du T, Leng X, Ding N, Zheng W, Song Y, Zhu J.

Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):269-72. doi: 10.3760/cma.j.issn.0253-2727.2016.04.002. Chinese.

PMID:
27093984
9.

Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.

Shin DY, Kim A, Byun BH, Moon H, Kim S, Ko YJ, Kim MJ, Lee HR, Kang HJ, Na II, Park S, Lee SS, Yang SH.

Ann Hematol. 2016 Feb;95(3):409-16. doi: 10.1007/s00277-015-2571-0. Epub 2015 Dec 10.

PMID:
26658607
10.

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP.

Br J Haematol. 2016 Jan;172(2):246-54. doi: 10.1111/bjh.13831. Epub 2015 Nov 18.

PMID:
26577576
11.

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ.

J Clin Oncol. 2016 Sep 10;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520. Epub 2016 Jul 5.

PMID:
27382100
12.

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S.

J Hematol Oncol. 2015 Jun 14;8:70. doi: 10.1186/s13045-015-0168-7.

13.

CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.

Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M.

Am J Hematol. 2013 Apr;88(4):273-6. doi: 10.1002/ajh.23398. Epub 2013 Mar 5.

14.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group.

Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.

PMID:
21940214
15.

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte.

Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4.

16.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.

Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.

17.

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.

Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0. Epub 2011 Dec 9.

PMID:
22160255
18.

The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.

Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB Jr.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):15-8. doi: 10.1016/j.clml.2012.09.009. Epub 2012 Nov 6.

19.

Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.

Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K, Orazi A, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Møller MB, Young KH, Tzankov A.

J Clin Pathol. 2013 Nov;66(11):956-61. doi: 10.1136/jclinpath-2013-201619. Epub 2013 Jun 17.

PMID:
23775435
20.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Lancet Oncol. 2013 May;14(6):525-33. doi: 10.1016/S1470-2045(13)70122-0. Epub 2013 Apr 9.

PMID:
23578722

Supplemental Content

Support Center